Merck & Co. Acquires Harpoon Therapeutics for ~$680M
Shots:
- Merck signed a definitive merger agreement to acquire Harpoon to enhance its oncology pipeline with Harpoon’s portfolio of novel T-cell engagers developed through the company’s TriTAC & ProTriTAC platform
- The acquisition includes Harpoon’s lead asset HPN328, a T-cell engager targeting DLL3, currently being evaluated in a P-I/II clinical trial for safety, tolerability & PK as monotx. in patient with advanced cancers associated with expression of DLL3 incl. SCLC. Harpoon’s pipeline also includes HPN217 & HPN601
- Under the terms of the agreement, Merck will acquire all outstanding shares of Harpoon for a price per share of $23.00 in cash for a total equity value of $680M. The transaction is expected to close by H1’24
Ref: Merck | Image: Harpoon Therapeutics
Related News:- Merck Reports the Initiation of a Series of P-III Trials for Bomedemstat, Nemtabrutinib, MK-2870 and MK-5684 to Treat Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.